Because of the limited number of isolation beds in the general ward and surgical bays, only the most drug-resistant infections and transmissible infections (eg, vancomycin-resistant enterococci and colistin-resistant Klebsiella pneumoniae, tuberculosis, and chickenpox) are given exceptional infection control priorities for isolation. Patients with ESBL producers, MRSA, and infectious diarrhea or vomiting-or even carbapenem-resistant gram-negative organisms-are isolated on the basis of the resources available and clinical needs.
To conclude, maintaining isolation facilities is a resourceintensive operation. Apart from making available a physically separable room, there is a need for separate ventilation, plumbing, pressure monitoring system, washing and toilet facilities, nursing care, physical barriers (such as double doors), and elaborate use of PPE. In resource-constrained settings, where the priority is to deliver a degree of care to the majority, high-quality measures such as providing an isolation facility that meets international standards may not be economically viable or practically feasible. From a health economic viewpoint, it may be more reasonable to provide highcost medical and surgical care to patients rather than utilizing the same resources for high-quality but resource-intensive isolation rooms.
The Tata Medical Center is a charitable, nonprofit institution. It aims to deliver state-of-the-art care to cancer patients. There is a need to individualize isolation policies and prioritize isolation based not only on infection concerns but also on clinical needs and resources available. Universal isolation or cohort nursing of patients infected with MDROs is viable when such patients are a minority. In high-prevalence settings, alternative solutions need to be explored. As members of the VA Antimicrobial Stewardship Task Force (ASTF), we are particularly interested in studies that demonstrate priority areas to improve antibiotic use. Their finding that 77% of patients received at least 1 unnecessary antimicrobial dose and that 26% received only unnecessary antimicrobials (apart from those directed against CDI) indicates ample opportunity to improve antimicrobial stewardship among our veteran patients with CDI. Furthermore, the estimate that 45% of total non-CDI antimicrobial days were unnecessary was not surprising given the frequently quoted estimate that approximately 50% of all antimicrobial use is inappropriate, regardless of setting.
2 Their findings are particularly notable given that the MVAMC uses highly sophisticated and robust computerized decision support 3 to assist providers in decision making regarding antimicrobial use; one might speculate that medical centers without similar computerized decision support might have even more unnecessary antimicrobial use in the context of CDI. We particularly agree that the period of time immediately following a CDI diagnosis is "a high-risk period when clinicians should be exercising increased caution with antimicrobial therapy."
1 To the antimicrobial steward, a CDI diagnosis thus represents a "call to arms"-a call we are addressing through a series of recently introduced programs, including one to address antibiotic use after CDI diagnosis.
The ASTF, since being chartered by the VA Office of Patient Care Services in May 2011," promotes the development and expansion of antimicrobial stewardship activities throughout the VA system. One function of the ASTF is to create model antimicrobial stewardship policies that can be adapted by individual VA facilities under the guidance of their pharmacy and therapeutics committees. Model polices are introduced and explained via monthly educational webinars and are made available through the ASTF SharePoint site, which serves as a forum for communication of ideas to promote good antimicrobial stewardship. In addition, ASTF members use the site to actively participate in the dissemination of information and tools that can be used by clinicians implementing and expanding antimicrobial stewardship programs. Minimum of 5 days; should be afebrile for 48-72 hours and have no more than 1 associated sign of clinical instability before discontinuation of therapy If initial antibiotic regimen is appropriate, consider shortening the duration of therapy from the traditional 14-21 days to periods as short as 7 days, provided that the etiologic pathogen is not Pseudomonas aeruginosa and that the patient has a good clinical response Continue antibiotic therapy until there is evidence that the infection has resolved but not necessarily until a wound has healed 1-2 weeks (though some require an additional 1-2 weeks) 2-4 weeks 4-6 weeks (shorter if entire infected bone is removed and probably longer if infected bone remains) 5-7 days or observation alone if no intravascular or orthopedic hardware is present and additional blood cultures (performed on samples collected when the patient is not receiving antibiotics) are obtained after catheter withdrawal to confirm the absence of bacteremia 4-6 weeks from first negative blood culture following catheter removal 6-8 weeks from first negative blood culture following catheter removal 7-10 days following catheter removal and incision and drainage (if  indicated) NOTE. CRBSI, catheter-related bloodstream infection; DFI, diabetic foot infection; MRSA, methicillin-resistant Staphylococcus aureus. " Non-guideline-based recommendation, based on Jenkins et al.
One model policy is an initiative that directs clinical pharmacists to review medication profiles of C. difficile-positive hospitalized patients to identify potential candidates for therapeutic interventions, with a particular focus on potentially unnecessary non-CDI-directed antimicrobial therapy. The policy recommends that severe CDI cases be referred for infectious diseases consultation. If a potential candidate for non-CDI antimicrobial therapy intervention is identified, the pharmacist communicates with the primary team through a templated note that addresses the importance of minimizing unnecessary antimicrobial exposure in patients with CDI. To assist stewards in making recommendations regarding duration of therapy, a table summarizing pertinent recommendations endorsed by the Infectious Diseases Society of America and other organizations was provided; a streamlined version of this table is presented here ( Table 1 ). The policy was presented and released to the VA community in August 2012. Based on preliminary follow-up of ASTF educational events, nearly half of all VA facilities reported that they were likely to prepare or update a policy limiting non-CDI-directed antibiotic exposure in order to improve outcomes for patients with CDI. Further system-wide evaluation of implementation and outcome-related utilization of the example CDI policy is planned.
Largely because of its integrated electronic medical record system and recent findings that indicate considerable variation in antimicrobial usage across VA medical centers nationwide, 5 we feel that the VA has immense potential to serve as a home for innovation in antimicrobial stewardship, and we look forward to ongoing discussions with our VA infectious diseases colleagues nationwide as to how we can best meet this potential. 
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